Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer

NCT02833506 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02833506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Withdrawn
Start date
December 8, 2017
Completion date
August 15, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, stage iia fallopian tube cancer, stage iia ovarian cancer, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iic fallopian tube cancer, stage iic ovarian cancer, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer